OasisLMS

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.

Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  
• Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

• Tina Cascone, MD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Corrine Faivre-Finn, MD, PhD, Professor, Thoracic Radiation Oncology, University of Manchester, UK
• Jacie Jiaqi Law, MBBCh, Cardiothoracic Surgery Specialist Trainee, Associate Surgery Specialty Lead in Thoracic Oncology, UK SCTS Academic and Research Division, Royal Brompton Hospital, London, UK
• Shankar Siva, MBBS, PhD, Associate Professor, Radiation Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia